Filing Flows › Insulet (PODD) › Q2 2026 › vs Q1 2026
Insulet (PODD) Q2 2026 vs Q1 2026 (quarter over quarter)
Insulet's revenue rose $40.0M (+5%) from $762M in Q1 2026 to $802M in Q2 2026. The biggest changes: Total Omnipod products +$37.4M (+5%); Drug Delivery +$2.5M (+76%). Gross margin 70.2% against 69.5% (+0.7 pts).
Insulet, Q2 2026: revenue $802M (+24% year over year), operating margin 16.2%, net earnings $95.0M, operating cash flow $88.4M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Gross margin | 70.2% | 69.5% | +0.7 pts |
| Operating margin | 16.2% | 16.0% | +0.1 pts |
| Net margin | 11.8% | 12.0% | -0.1 pts |
| Free cash flow margin | 7.0% | 11.8% | -4.8 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| U.S. | $544M | $516M | $28.5M | +6% |
| International | $252M | $243M | $8.9M | +4% |
| Total Omnipod products | $796M | $758M | $37.4M | +5% |
| Drug Delivery | $5.8M | $3.3M | $2.5M | +76% |
| Revenue | $802M | $762M | $40.0M | +5% |
| Gross profit | $563M | $529M | $33.5M | +6% |
| Cost of revenue | $239M | $233M | $6.5M | +3% |
| Operating profit | $130M | $122M | $7.6M | +6% |
| Operating expenses | $433M | $407M | $25.9M | +6% |
| Pre-tax earnings | $119M | $113M | $5.7M | +5% |
| Other expense, net | $11.0M | $9.1M | $1.9M | +21% |
| Research & development | $88.1M | $89.7M | −$1.6M | -2% |
| SG&A | $345M | $317M | $27.6M | +9% |
| Net earnings | $95.0M | $91.1M | $3.9M | +4% |
| Income tax | $23.7M | $21.9M | $1.8M | +8% |
| Depreciation & amortization | $26.7M | $26.2M | $500K | +2% |
| Share-based compensation | $19.6M | $21.3M | −$1.7M | -8% |
| Working capital & other | $52.9M | $24.8M | $28.1M | +113% |
| Operating cash flow | $88.4M | $114M | −$25.4M | -22% |
| Free cash flow (OCF − capex) | $55.9M | $89.5M | −$33.6M | -38% |
| Capital expenditures | $32.5M | $24.3M | $8.2M | +34% |
Questions
How much did Insulet's revenue grow quarter over quarter in Q2 2026?
Insulet's revenue rose $40.0M (+5%) from $762M in Q1 2026 to $802M in Q2 2026.
What drove Insulet's revenue change in Q2 2026?
Total Omnipod products +$37.4M (+5%); Drug Delivery +$2.5M (+76%).